General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
BORTEZOMIB
BORTEZOMIB
Standard Dose
3.5MG/1.4ML (2.5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 212782 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength SOLUTION;INTRAVENOUS, SUBCUTANEOUS - 3.5MG/1.4ML (2.5MG/ML) Sponsor SHILPA Submission history Latest submission status date: 2024-08-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 212782 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength SOLUTION;INTRAVENOUS, SUBCUTANEOUS - 3.5MG/1.4ML (2.5MG/ML) Sponsor SHILPA Submission history Latest submission status date: 2024-08-26 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.